The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse disease progression and repair lung tissue. Smoking cessation is the only way to slow or halt disease progression; therapies that can reverse pathological processes and regenerate alveolar tissue have yet to be discovered. In the absence of a truly disease-modifying therapy, inhaled bronchodilator therapies are usually prescribed, and drug development has focused on improving breathing or reducing inflammation. Although inhaled medications are primarily effective in reducing the burden of COPD by easing its symptoms, patients’ quality of life still suffers. Thus, significant unmet need remains for more-effective therapies, especially for patients with severe COPD.
- What clinical and nonclinical attributes are key influencers to pulmonologists’ prescribing decisions, which have limited impact, and what are potential areas of hidden opportunity?
- How do current therapies (e.g., Boehringer Ingelheim’s Spiriva, GlaxoSmithKline’s Advair /Seretide, AstraZeneca’s Symbicort, GSK / Innoviva’s Anoro, BI’s Stiolto / Spiolto, GSK’s Trelegy) perform on key treatment drivers and goals for COPD?
- How do key clinical and nonclinical attributes impact pulmonologists’ preference for and likelihood to prescribe a hypothetical new COPD drug?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European pulmonologists fielded in February 2020
Key companies: GSK, Boehringer Ingelheim, AstraZeneca, Novartis
Key drugs: Spiriva, Advair / Seretide, Symbicort, Utibron / Ultibro, Anoro, Stiolto / Spiolto, Trelegy